Daylife Select
A point & click tool to create dynamic content portals. Learn More »
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT. Full Article at Motley Fool
Today Katie McQue Please Login to read the full article. Full Article at Scrip News
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (L), in New York, August 6, 2009. View Photo »
So in these cases we had people with breast cancer and associated damages, I think in the Pfizer cases there were awards of up to $4 million for compensatory damages but awards of say up to $70 million for punitive. So the compensatory component would be available to people in this country.
While global merger and acquisition activity is down by as much as 41% this year according to The Mergermarket Group, don't tell that to lawyers at Cassels, Brock & Blackwell. Full Article at Financial Post
Patent disputes are hardly out of the ordinary, but the big drugmaker is locked in an interesting battle in this SouthEast Asian nation, where UniLab UniLab is importing and selling a generic version of the best-selling cholesterol drug. Full Article at Pharmalot
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009. View Photo »
Pfizer might part with its recently acquired Wyeth baby-food business ... It's all formula, which Heinz loves; there would be no antitrust concerns; and it's not as big as Mead Johnson.
Pfizer will expand its clinical services and biomedical presence in China as part of a worldwide effort to develop its R&D infrastructure. Full Article at InPharmaTechnologist
Once spurned by drugmakers as low-margin and risky, vaccines to fight diseases such as H1N1 are now a growing business for Novartis and others. Full Article at Spiegel Online
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (L), in New York, August 6, 2009.
View Photo »Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009.
View Photo »Graphic shows 2008 sales for selected Pfizer drugs.
View Photo »Graphic shows 2008 sales for selected Pfizer drugs.
View Photo »Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, shake hands after a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »Jeffrey Kindler, Chairman and CEO of Pfizer, smiles during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo »Jeffrey Kindler, Chairman and CEO of Pfizer, speaks during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo »Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, shake hands after a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »Jeffrey Kindler, Chairman and CEO of Pfizer, smiles during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo »Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, attend a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »Jeffrey Kindler, (L) Chairman and CEO of Pfizer and Bernard Poussot, Chairman and CEO of Wyeth, speak during a press conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, attend a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, speak during a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo »NEW YORK - JANUARY 22: (FILE PHOTO) The Pfizer building is seen January 22, 2007 in New York City.
View Photo »NEW YORK - APRIL 17: (FILE PHOTO) Pedestrians walk past the world headquarters of Pfizer Inc. April 17, 2008 in New York City.
View Photo »Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference Monday, Jan. 26, 2009, in New York.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion creating the world's largest biopharmaceutical company.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion creating the world's largest biopharmaceutical company.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »NEW YORK - JANUARY 26: A Pfizer sign hangs on the outside of their headquarters after a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion, creating the world's largest biopharmaceutical company.
View Photo »NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009.
View Photo »So in these cases we had people with breast cancer and associated damages, I think in the Pfizer cases there were awards of up to $4 million for compensatory damages but awards of say up to $70 million for punitive. So the compensatory component would be available to people in this country.
Pfizer might part with its recently acquired Wyeth baby-food business ... It's all formula, which Heinz loves; there would be no antitrust concerns; and it's not as big as Mead Johnson.
The leadership contributions from SFU, Pfizer Canada, the Heart and Stroke Foundation and the anonymous donor to St. Paul's Hospital Foundation for this Chair will have a dramatic impact on heart disease prevention at St. Paul's Hospital and SFU, improving the health of people in B.C. and beyond
The approval of Revatio injection is a clear demonstration of Pfizer’s commitment to developing treatments addressing the unmet needs of patients with pulmonary arterial hypertension. This important milestone highlights the Specialty Care business unit’s dedication to advancing treatments for serious an...
Now if you'll excuse me, I have to go eat lunch with representatives from Goldman Sachs, Wells Fargo and Pfizer.
The Southeastern Pennsylvania Transportation Authority has agreed to cover almost all of its rising health-care costs, and to increase coverage for Pfizer’s (PFE) Viagra and other erectile dysfunction treatments, the Philadelphia Daily News reports. Workers are unhappy that their health insurance plan o...
Today’s announcement that Pfizer is closing its research facility in New London demonstrates the folly of government plans that involve massive corporate welfare and that abuse eminent domain for private development. The majority opinion in Kelo v. New London described the Fort Trumbull project as a ‘ca...
How wonderful would it be that the remediation of Pfizer be included in the rezoning of the Broadway Triangle
The announced closing of the New London site eight years after it opened to great fanfare came as a blow to a city that had counted on Pfizer’s multimillion-dollar facility to help revive its fortunes
California has always been a leader in biotech research and innovation and Pfizer's announcement that it will establish California as one (of) the five hubs of its worldwide R&D network is fantastic news for our state ... Today's announcement will not only ensure that our state continues as a leader in ...
This Chesterfield Village Research Center is truly a world-class facility and our agreement with Pfizer will enable both of our companies to maintain our deep research roots in St. Louis for years to come
The ASA has received 48 complaints about the Pfizer TV ad. We are currently assessing the complaints to establish whether or not there are grounds for an investigation.
I think it's just that, frankly, with the acquisition of Wyeth, Pfizer had more than 20 research and development facilities, and they had to look at ways to streamline and consolidate. I believe that the work that's being done in (South Brunswick) is being moved up to their Groton, Conn., facility, whic...
Legally, Pfizer India and Wyeth India are two separate entities. They have separate boards and will therefore function separately. The products of Pfizer and Wyeth are complementary
Legally, Pfizer India and Wyeth India are two separate entities. They have separate boards and will therefore function separately. The products of Pfizer and Wyeth are complementary
As of now, Wyeth and Pfizer are two separate entities and they do not have major overlaps in terms of product portfolios and rather they complement each other
To fuel the growth of Pfizer in India, we are also expanding our operations in tier-2 and tier-3 cities
At quarter end, the six largest disclosed long positions in the Partnerships are Arkema, CIT Group debt, Ford Motor Company debt, gold, Lanxess and Pfizer. The Partnerships had an average exposure to equities and fixed income (excluding credit derivatives, gold and foreign currencies) of 99% long and 59...
The upgrade of Wyeth's ratings is based on the execution of an unconditional and irrevocable guarantee of Wyeth's outstanding bonds from Pfizer
We have settled and we are signing an agreement , Kano State government has finally reached a $75 million settlement agreement with Pfizer Pharmaceutical Company, over the 1996 Trovan test in the state
The Board's action continues Pfizer's long tradition of seeking and responding to shareholder input on compensation and other corporate governance topics
We are proud to have worked closely with Pfizer on the design and construction of this state-of-the-art facility. Equally important, we are pleased to note that the building was delivered on time and on budget
Pfizer financed $22.5 billion in loans from banks that received at least $75 billion from the Treasury Department’s rescue plan.
While the court understands there may be some delay in producing discovery, Pfizer did not represent to the court that its production would be a long slow rolling production ... In the court's view the record reveals that Pfizer's conduct has not risen to a level of willful and intentional disobedience....
- michaelmcalpine
37 minutes ago
- CandleCourse
3 hours ago
- MyPills
12 hours ago
- weltfried
13 hours ago
- WallStNation
17 hours ago
